Abstract

The microphthalmia associated transcription factor (MITF) is a critical regulator of melanocyte development and differentiation. It also plays an important role in melanoma where it has been described as a molecular rheostat that, depending on activity levels, allows reversible switching between different cellular states. Here we show that MITF directly represses the expression of genes associated with the extracellular matrix (ECM) and focal adhesion pathways in human melanoma cells as well as of regulators of epithelial to mesenchymal transition (EMT) such as CDH2, thus affecting cell morphology and cell-matrix interactions. Importantly, we show that these effects of MITF are reversible, as expected from the rheostat model. The number of focal adhesion points increased upon MITF knockdown, a feature observed in drug resistant melanomas. Cells lacking MITF are similar to the cells of minimal residual disease observed in both human and zebrafish melanomas. Our results suggest that MITF plays a critical role as a repressor of gene expression and is actively involved in shaping the microenvironment of melanoma cells in a cell-autonomous manner.

Data availability

MITF CUT&RUN sequencing data have been deposited in GEO under accession codes GSE153020 and the RNA-Seq data discussed in this publication are available under the accession number GSE163646.

The following previously published data sets were used

Article and author information

Author details

  1. Ramile Dilshat

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2126-2902
  2. Valerie Fock

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  3. Colin Kenny

    Department of Anatomy and Cell biology, Carver College of Medicine, University of Iowa, Iowa, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Ilse   Gerritsen

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  5. Romain Maurice Jacques Lasseur

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  6. Jana Travnickova 

    MRC Institute of Genetics and Molecular Medicine, MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Ossia Margarita Eichhoff 

    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3319-1312
  8. Philipp Cerny

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  9. Katrin Möller

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  10. Sara Sigurbjörnsdóttir 

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  11. Kritika Kirty

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  12. Berglind Ósk Einarsdottir

    Department of Biochemistry and Molecular Biology, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  13. Phil F Cheng

    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2940-006X
  14. Mitchell Levesque

    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  15. Robert A Cornell

    College of Medicine, University of Iowa, Iowa City, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4207-9100
  16. E Elizabeth Patton

    MRC Human Genetics Unit, MRC Institute for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2570-0834
  17. Lionel Larue

    Institut Curie, Orsay, France
    Competing interests
    The authors declare that no competing interests exist.
  18. Marie de Tayrac 

    CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, F-35000, Univ Rennes1, Rennes, France
    Competing interests
    The authors declare that no competing interests exist.
  19. Erna Magnúsdóttir 

    Department of Anatomy, BioMedical Center, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3369-4390
  20. Margrét Helga Ögmundsdóttir

    Department of Biochemistry and Molecular Biology, University of Iceland, Reykjavik, Iceland
    Competing interests
    The authors declare that no competing interests exist.
  21. Eirikur Steingrimsson

    Department of Biochemistry, University of Iceland, Reykjavik, Iceland
    For correspondence
    eirikurs@hi.is
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5826-7486

Funding

Icelandic Centre for Research (184861 and 767 207067)

  • Eirikur Steingrimsson

National Institutes of Health (A2062457)

  • Robert A Cornell

H2020 European Research Council (ZF-MEL-CHEMBIO-648489)

  • E Elizabeth Patton

L'Oreal Melanoma Research Alliance (401181)

  • E Elizabeth Patton

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Dilshat et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,903
    views
  • 498
    downloads
  • 56
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ramile Dilshat
  2. Valerie Fock
  3. Colin Kenny
  4. Ilse   Gerritsen
  5. Romain Maurice Jacques Lasseur
  6. Jana Travnickova 
  7. Ossia Margarita Eichhoff 
  8. Philipp Cerny
  9. Katrin Möller
  10. Sara Sigurbjörnsdóttir 
  11. Kritika Kirty
  12. Berglind Ósk Einarsdottir
  13. Phil F Cheng
  14. Mitchell Levesque
  15. Robert A Cornell
  16. E Elizabeth Patton
  17. Lionel Larue
  18. Marie de Tayrac 
  19. Erna Magnúsdóttir 
  20. Margrét Helga Ögmundsdóttir
  21. Eirikur Steingrimsson
(2021)
MITF reprograms the extracellular matrix and focal adhesion in melanoma
eLife 10:e63093.
https://doi.org/10.7554/eLife.63093

Share this article

https://doi.org/10.7554/eLife.63093

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.